Research Analysts Set Expectations for VYGR Q3 Earnings

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Voyager Therapeutics in a research note issued on Wednesday, October 16th. Leerink Partnrs analyst L. Nsongo forecasts that the company will post earnings of ($0.08) per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.44) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics’ Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.44) EPS, FY2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.85) EPS and FY2028 earnings at ($0.22) EPS.

Several other research firms also recently issued reports on VYGR. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Tuesday, August 20th. Wedbush cut their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday. They set an “outperform” rating and a $15.00 price objective for the company. Finally, StockNews.com raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, October 11th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $17.43.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $8.01 on Friday. The stock has a market cap of $435.70 million, a PE ratio of -160.20 and a beta of 0.91. The stock has a 50-day moving average of $6.51 and a two-hundred day moving average of $7.73. Voyager Therapeutics has a one year low of $5.71 and a one year high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The business had revenue of $29.58 million for the quarter, compared to the consensus estimate of $11.52 million. During the same period in the prior year, the firm posted ($0.51) earnings per share.

Hedge Funds Weigh In On Voyager Therapeutics

Several institutional investors have recently made changes to their positions in VYGR. Ameritas Investment Partners Inc. grew its position in Voyager Therapeutics by 49.6% during the first quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after buying an additional 1,300 shares during the period. Victory Capital Management Inc. boosted its stake in shares of Voyager Therapeutics by 14.5% during the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares in the last quarter. SummerHaven Investment Management LLC grew its position in shares of Voyager Therapeutics by 2.5% during the 2nd quarter. SummerHaven Investment Management LLC now owns 77,293 shares of the company’s stock valued at $611,000 after acquiring an additional 1,921 shares during the period. Hunter Perkins Capital Management LLC increased its stake in shares of Voyager Therapeutics by 3.3% in the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after purchasing an additional 2,025 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Voyager Therapeutics by 2.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock worth $925,000 after purchasing an additional 2,030 shares during the period. 48.03% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at $500,525.82. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 4.53% of the stock is currently owned by corporate insiders.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.